{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-074130","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.591520+00:00","generated_at":"2026-06-01T02:30:06.846161+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada Therapeutics raises $100M in registered direct offering to fund pipeline","bullets":["Gross proceeds of $100M from sale of 3,367,003 shares at $14.85 and pre-funded warrants at $14.8499.","Offering led by U.S. healthcare-focused investor, two global mutual funds, and Janus Henderson.","Proceeds to fund Phase 2b trials for ENTR-601-44/45 and Phase 2 MAD trial for ENTR-601-50.","Expected closing on June 25, 2024; cash runway extended into 2027.","30-day lockup on new equity issuance and registration statements."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-074130","json":"https://secwatch.observer/filing/0001104659-24-074130.json","markdown":"https://secwatch.observer/filing/0001104659-24-074130.md","text":"https://secwatch.observer/filing/0001104659-24-074130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465924074130/0001104659-24-074130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465924074130/tm2417848d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:30:06.846161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}